Advertisement

Browse Subject Areas

?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

Loading metrics

Open Access

Correction

Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

The PLOS ONE Editors

Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

The PLOS ONE Editors

x

Published: October 20, 2022
https://doi.org/10.1371/journal.pone.0276650

Reader Comments (0)

Post a new comment on this article